Status:
UNKNOWN
Gut Microbiota, SCFAs and Glucolipid Metabolism in Pregnant Women With Abnormal Fetal Size and Their Newborns
Lead Sponsor:
Second Affiliated Hospital of Wenzhou Medical University
Conditions:
Fetal Growth Restriction
Gut Microbiota
Eligibility:
FEMALE
18-40 years
Brief Summary
Abnormal fetal size includes fetal growth restriction and fetal macrosomia. Onset is closely related to maternal nutrition metabolism. The specific correlation and mechanism is unclear, and there are ...
Eligibility Criteria
Inclusion
- Singleton pregnancy
- Term pregnancy with the gestational age of 37-40 weeks
Exclusion
- Maternal systemic diseases (hypertension disorders, immunological diseases) or pregnant complications (polyhydramnios, oligohydramnios, diabetes mellitus, intrahepatic cholestasis of pregnancy)
- Delivery before 37 weeks or after 40 weeks
- Neonates had major congenital malformations (congenital anal atresia, congenital biliary atresia, congenital heart disease)
Key Trial Info
Start Date :
January 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2020
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04399434
Start Date
January 1 2019
End Date
October 1 2020
Last Update
May 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
department of obstetrics of Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China, 325027